Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.48 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | CCR6 | P51684 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7082412 | 0.88 | LMNA (0.53) | MEN1KMT2ALMNAMCOLN3HTT | |
| SCHEMBL7075094 | 0.85 | MEN1 (0.48) | MEN1KMT2ALMNAHTTALDH1A1 | |
| SCHEMBL7079602 | 0.84 | ALDH1A1 (0.64) | MEN1KMT2ALMNAHTTALDH1A1 | |
| SCHEMBL7075758 | 0.81 | PKM (0.63) | MEN1KMT2ALMNAHTTALDH1A1 | |
| SCHEMBL7080360 | 0.81 | LMNA (0.52) | MEN1KMT2ALMNAHTTALDH1A1 | |
| SCHEMBL10702111 | 0.80 | LMNA (0.56) | MEN1KMT2ALMNAHTTALDH1A1 | |
| SCHEMBL7109414 | 0.78 | LMNA (0.51) | MEN1KMT2ALMNAHTTALDH1A1 | |
| SCHEMBL7079622 | 0.76 | HTR1A (0.55) | MEN1KMT2ALMNAHTTALDH1A1 | |
| SCHEMBL23052441 | 0.74 | ALDH1A1 (0.64) | MEN1KMT2AALDH1A1POLBUCHL1 | |
| SCHEMBL14923992 | 0.73 | USP30 (0.64) | MEN1KMT2ALMNAMCOLN3HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030158186-A1 | Compositions and methods for treating heart failure | CYTOKINETICS, INCORPORATED | 2003-08-21 | — | — | US | disclosed |
| WO-2003059265-A2 | COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE | CYTOKINETICS, INC. (US) | 2003-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158186-A1 | Compositions and methods for treating heart failure | MYH2, TNNI3, MYLK2 | MEN1 4537/4885KMT2A 2747/4885LMNA 228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.